Abstract Number: 2617 • 2015 ACR/ARHP Annual Meeting
Serum 14-3-3eta Protein Elevation in Osteoarthritis Suggests Misclassification or Concurrent Inflammatory Arthritis
Background/Purpose: Tissue distribution of the chaperonin 14-3-3η (eta) is limited to synovial tissue and brain. Synovium releases proinflammatory 14-3-3η into synovial fluid and serum in…Abstract Number: 3100 • 2015 ACR/ARHP Annual Meeting
Anti-RA33 Citrullinated/Native Double-Reactive Antibodies Identify Patients with the Highest Risk of Radiographic Progression in Rheumatoid Arthritis
Background/Purpose: Antibodies against RA33 (hnRNP A2/B1) were one of the earliest antigen specificities identified in rheumatoid arthritis (RA). Unlike the erosive disease associated with anti-citrullinated…Abstract Number: 312 • 2015 ACR/ARHP Annual Meeting
Safety, Efficacy and Biomarker Outcomes of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study
Background/Purpose: Knee osteoarthritis (OA) is characterized by the destruction of articular cartilage, subchrondral bone alterations and varying degrees of synovitis. Current OA treatments are limited…Abstract Number: 757 • 2015 ACR/ARHP Annual Meeting
The Ratio Between TNF-a and P-Albumin – a Suggested Measure of Disease Activity in SLE
Background/Purpose: There is presently no consensus on how to best measure disease activity in systemic lupus erythematosus (SLE). Available validated measures, such as SLE Disease…Abstract Number: 1241 • 2015 ACR/ARHP Annual Meeting
Identification and Validation of Diagnostic and Activity Urinary Metabolomic Biomarkers in Immune-Mediated Inflammatory Diseases
Background/Purpose: The recent advances in metabolomics have allowed the study of the regulatory processes linked to metabolism. The comprehensive analysis of the metabolome in biological samples…Abstract Number: 1737 • 2015 ACR/ARHP Annual Meeting
Increased Osteoclast Precursors with an Elevated DC-STAMP Expression May Identify Psoriasis Patients at Risk for Psoriatic Arthritis
Background/Purpose: Approximately 25% of psoriasis (Ps) patients develop into psoriatic arthritis (PsA) within 10 years. This Ps-to-PsA transition paradigm provides a unique opportunity to recognize…Abstract Number: 2065 • 2015 ACR/ARHP Annual Meeting
Verification of Novel Soluble Biomarkers That Differentiate Patients with Psoriatic Arthritis from Those with Psoriasis without Psoriatic Arthritis
Background/Purpose: There is a high prevalence of undiagnosed psoriatic arthritis (PsA) in psoriasis patients. Therefore identifying soluble biomarkers for PsA will help in screening psoriasis…Abstract Number: 2677 • 2015 ACR/ARHP Annual Meeting
Targeting Biomarkers of Nitric Oxide and Endothelial Dysfunction in Patients with Rheumatoid Arthritis
Background/Purpose: Numerous studies have reported increased cardiovascular morbidity and mortality in rheumatoid arthritis (RA) patients that cannot be explained by traditional risk factors. In a…Abstract Number: 3108 • 2015 ACR/ARHP Annual Meeting
Serum 14-3-3eta Are Elevated in Indigenous North Americans with Rheumatoid Arthritis and May Predict Imminent Synovitis in Their at-Risk First Degree Relatives
Background/Purpose: Indigenous North Americans (INA) have high prevalence rates of severe erosive rheumatoid arthritis (RA). We have established a cohort of unaffected first degree relatives…Abstract Number: 478 • 2015 ACR/ARHP Annual Meeting
Impact of Comorbidities on the Multi-Biomarker Disease Activity Test in Rheumatoid Arthritis Patients
Background/Purpose: The multi-biomarker disease activity (MBDA) score [Vectra] has been evaluated in a number of settings, yet has only limited data evaluating whether it is…Abstract Number: 770 • 2015 ACR/ARHP Annual Meeting
Circulating Levels of iC3b and C3 Correlate with Sledai-2K Responder Index-50 (S2K RI-50) Disease Activity Scores: The Castle (Complement Activation Signatures in Systemic Lupus Erythematosus) Study
Background/Purpose: A major unmet need in SLE is the identification of a biomarker that consistently tracks with disease activity. One current approach is measuring complement…Abstract Number: 1243 • 2015 ACR/ARHP Annual Meeting
Identification of the Gene Expression Signatures Predicting the Responses to Three Biologics (infliximab, tocilizumab, and abatacept) in Rheumatoid Arthritis
Background/Purpose: Employing genome-wide gene transcription on a unified platform, to identify molecular signatures for predicting therapeutic effects for rheumatoid arthritis (RA) with three biologics, infliximab…Abstract Number: 1742 • 2015 ACR/ARHP Annual Meeting
Fingerprint Biomarkers of Type I and III Collagen in Axial Spondyloarthropathy (axSpA) and Psoriatic Arthritis (PsA). Association with Disease Activity and Diagnostic Capacity
Background/Purpose: AxSpA and PsA are core members of the spondyloarthritis complex. One cardinal characteristic shared by these two conditions is increased remodeling of bone and…Abstract Number: 2066 • 2015 ACR/ARHP Annual Meeting
Elevated Innate, Adaptive, and TNF-Superfamily Soluble Inflammatory Mediators Mark Impending Disease Flare, While Regulatory Mediators Distinguish Lack of Impending Disease Flare in African-American SLE Patients with Active Disease
Background/Purpose: SLE is a multifaceted disease characterized by immune dysregulation and varied disease activity. Identifying mechanistic mediators of altered disease activity would help prevent damage…Abstract Number: 2694 • 2015 ACR/ARHP Annual Meeting
Variations in the Metabolome in Response to Disease Activity of Rheumatoid Arthritis
Background/Purpose: Anti-TNF-alpha therapies are able to control rheumatoid arthritis (RA) disease activity and to limit structural damage. Nevertheless, no predictive factor of response to anti-TNF-alpha,…
- « Previous Page
- 1
- …
- 63
- 64
- 65
- 66
- 67
- …
- 83
- Next Page »